Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease - 22/07/20

Disclosure of potential conflict of interest: R. Caorsi receives speaker’s fees and has consultancies for Novartis and SOBI. A. Ravelli receives speaker’s fees and has consultancies for Novartis and SOBI. M. Gattorno receives speaker’s fees and has consultancies for Novartis and SOBI. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 146 - N° 1
P. 213-215 - juillet 2020 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.